Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stable New York Heart Association (NYHA) Class II-IV heart failure symptoms for at least 4 weeks before study entry~* Diagnosis of diastolic heart failure with a normal ejection fraction~* Admitted to the hospital with a diagnosis of heart failure in the 12 months before study entry~* Type 2 diabetes~Exclusion Criteria:~* Unstable angina, heart attack, coronary artery bypass surgery, or angioplasty in the 3 months before study entry~* Angina with exertion~* Technically inadequate echocardiogram~* Atrial fibrillation or atrial flutter~* Severe valvular heart disease~* Significant kidney insufficiency (serum creatinine greater than 2.0 mg/dL or require hemodialysis)~* Conditions that may be associated with changes in markers of fibrosis or collagen turnover (e.g., ongoing or active rheumatological disease, requiring significant anti-inflammatory agents, immunosuppression, pulmonary fibrosis, active cancer)~* Significant history of active substance abuse~* Type 1 diabetes~* Type 2 diabetes requiring chronic insulin use before study entry~* Active thiazolidinedione (TZD) use, because TZDs have been shown to worsen volume retention and may exacerbate signs and/or symptoms of heart failure~* Pregnant or breastfeeding~* Hypertrophic cardiomyopathy

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: NO_INTERVENTION): Participants will receive usual care for 12 weeks. The care will be dictated by the primary physician and/or diabetologist caring for the participant. Efforts will be made to ensure that all participants receive standard measures as indicated by guidelines, with a particular emphasis on blood pressure control and glucose control.
- 2 (Type: EXPERIMENTAL): Participants will receive exenatide for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).